Bioequivalence of Two NovoLog® Formulations in Subjects With Type 1 Diabetes

Inclusion Criteria: * Subjects with type 1 diabetes treated with insulin for at least 12 months * BMI (Body Mass Index) between 18.0-29.0 kg/m\^2 * Negative fasting C-peptide (below or equal to 0.6 ng/mL) * HbA1c (glycosylated haemoglobin A1c) below or equal to 10.0% * Current treatment with insulin below or equal to 1.2 U/kg/day * Subject should be in good health based on medical history, physical examination and routine laboratory data Exclusion Criteria: * Any known/suspected allergies to trial medication or similar products/devices * A subject who has proliferative retinopathy or maculopathy, and/or severe neuropathy, in particular autonomic neuropathy, as judged by the Investigator * Clinically significant active disease of any kind * Recurrent major hypoglycemia or hypoglycemic unawareness, as judged by the Investigator * Blood donation (more than 500 mL) within the previous 9 weeks